Raj Chovatiya, MD, PhD

This interview at RAD 2025 highlights several notes on dose flexibility in atopic dermatitis, with commentary by presenter Raj Chovatiya, MD, PhD.

An expert discusses how new treatments for chronic hand eczema (CHE) are emerging, particularly topical delgocitinib cream, a pan-Janus kinase (JAK) inhibitor that shows promise for treating multiple etiologies of the condition without the limitations of traditional topical steroids.

In this interview, Mona Shahriari, MD, and Raj Chovatiya, MD, PhD, touched on the evolving role of pharmacists and internal medicine doctors in atopic dermatitis.

An expert discusses how chronic hand eczema (CHE) treatment follows a stepwise approach from general care and barrier protection to topical therapies (corticosteroids and calcineurin inhibitors) and systemic options (alitretinoin, immunosuppressives, and newer biologics for atopic dermatitis).

An expert discusses how chronic hand eczema (CHE) significantly impacts patients' daily activities and work productivity, as painful symptoms and limitations make routine tasks challenging, while avoidance recommendations are often difficult to implement.

An expert discusses how chronic hand eczema (CHE) diagnosis relies on clinical features such as erythema, scaling, vesicles, hyperkeratosis, fissures, and erosions, which must be distinguished from atopic dermatitis through a comprehensive patient history and full-body examination.

An expert discusses how risk factors for chronic hand eczema (CHE) include atopic dermatitis, filaggrin mutations, contact allergies, environmental conditions, and occupational exposures, with hand eczema being the most common occupational skin disease.

In this interview, Raj Chovatiya, MD, PhD, describes roflumilast cream's success in addressing unmet needs for atopic dermatitis.

An expert discusses how chronic hand eczema (CHE) presents in various clinical and etiologic subtypes, including irritant and allergic contact dermatitis, atopic hand eczema, and protein contact dermatitis, with clinical manifestations ranging from hyperkeratotic to vesicular forms.

An expert discusses how chronic hand eczema (CHE) is a common condition affecting 1% to 5% of adults and is defined as hand eczema lasting at least 3 months or relapsing at least 2 times per year, distinct from atopic dermatitis.

In this interview, Chovatiya and Shahriari highlight notable elements of the upcoming Revolutionizing Atopic Dermatitis (RAD) Conference.

Revolutionizing Atopic Dermatitis 2025 Annual Meeting cochair Raj Chovatiya, MD, PhD, previews the upcoming meeting.

A pair of experts discuss unmet needs and educational gaps related to atopic dermatitis.

In this interview, Chovatiya highlighted the unmet needs of patients with atopic dermatitis and the ways in which nemolizumab’s FDA approval addresses them.

This interview with Chovatiya highlights his portion of the ‘Skin of Color’ talk at the American Academy of Dermatology conference.

This summary, featuring 4 leading experts, provides an overview of what dermatologists may look forward to during the AAD 2025 Annual Meeting.

Chovatiya discussed his talk at the 2025 AAAAI/WAO Joint Congress.

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.